HPGDS and cancer: This experimental model was designed to observe events occurring at the very beginning of cancer development and to determine whether the tested compound can significantly reduce key markers, glutathione S-transferase placental form (GST-P)-positive foci in the liver, and aberrant crypt foci (ACF) formation in the colon.